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SUMMARY
The advancement in technology, particularly in the field of omics, has led to numerous discoveries 
of biomarkers for early post-HSCT complications. Future research must include the testing of 
newly discovered biomarkers against existing, validated biomarkers. Work also needs to be done to 
implement the promising, validated biomarkers into clinical practice in a time-efficient and cost-
effective manner. The prognostic biomarkers should be incorporated into clinical trials so that the 
effect of early recognition on the outcomes of HSCT recipients can be assessed. Diagnostic 
biomarkers can help to differentiate the complex variety of diseases that can be present in this 
population. Finally, biomarkers that can serve as therapeutic targets should be further studied. 
Many of these post-HSCT complications have limited or nonspecific therapeutic options. For 
example, corticosteroids are the first-line therapy for aGVHD. Using biomarkers to help identify 
underlying biologic pathways may open new therapeutic avenues that deserve investigation. This 
major advancement in technology allows for early diagnosis of complications, risk stratification 
for complications, and potential new therapeutic targets. All of these strides can improve the 
utilization of life-saving allogeneic HSCT while minimizing complications and mortality.
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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is increasingly being used for a variety of 
malignant and nonmalignant conditions. With improvements in donor selection and 
conditional regimens, outcomes have improved. However, early posttransplant complications 
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remain a barrier for overall success and survival. Issues such as acute graft-versus-host 
disease (aGVHD), sinusoidal obstructive syndrome (SOS), and idiopathic pneumonia 
syndrome (IPS) can dramatically increase morbidity and mortality. For example, up to one-
half of patients who have undergone allogeneic HSCT can be affected by aGVHD1 and are 
at increased risk for mortality.
Biomarkers can offer an effective method for early identification of complications related to 
HSCT and potentially guide treatments. Biomarkers have gained popularity over the years as 
a way to provide objective, unbiased information. As technology has advanced, there has 
been an explosion in the development and applications of biomarkers in an array of 
specialties. These markers can be obtained from a variety of medical samples, such as blood 
and urine, but can also be thought of in the broader sense to include data such as 
radiographic images obtained from use of other technologies. An ideal biomarker would be 
obtained from a readily available, noninvasive sample that could be easily collected at 
multiple time points. Currently, plasma and serum remain the most common sources for 
biomarkers and effectively provide information on systemic disorders that often affect the 
transplant recipient, such as aGVHD.
In a National Institutes of Health–sponsored working group, biomarkers were categorized 
into 4 types: diagnostic, prognostic, predictive, and response to treatment2 (Table 1). A 
diagnostic biomarker helps a clinician identify a disease rapidly or differentiate between 
diseases with similar presentations. A prognostic biomarker should aid a clinician in the 
anticipated course of a disease or the development of a particular complication. A predictive 
biomarker gives information about how a patient or disease progression will likely respond 
to a specific treatment, therapy, or intervention when measured before the treatment. Finally, 
a response to treatment marker can be used to monitor the treatment response and could 
substitute for a clinical response endpoint. Unlike a predictive marker, it is measured after 
treatment is initiated to monitor therapeutic response.
OMICS TECHNOLOGIC ADVANCES AND THE DEVELOPMENT OF 
BIOMARKERS
The recent technologic advances combined with their decreasing cost have led to a rapid 
increase in the application of omics in translational research and then in clinic. There are 
many different types of omics, but the most popular remain genomics, transcriptomics, and 
proteomics. The foundation of the omics field was built on genomics, which is the study of 
how genetic variants are associated with disease development or prognosis. In addition, it is 
being increasingly applied to stratify patients at risk for adverse events to certain drugs (ie, 
pharmacogenomics). Transcriptomics measure gene activity by investigating the messenger 
RNA that codes for different proteins. Proteomics investigates protein quantity and function. 
It is important because it measures both gene function and the host environment, but is 
complicated due to the sheer volume of proteins. These omics all carry different importance. 
For this review, the authors focus on the most relevant and recent biomarkers that have been 
validated in different cohorts.
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The development of a biomarker is complicated and involves many steps from discovery to 
implementation in the routine clinical care of patients. Fig. 1 highlights the important steps 
of development. These steps must all be followed to ensure the validity and clinical utility of 
newly discovered biomarkers.
BIOMARKERS FOR EARLY COMPLICATIONS AFTER HEMATOPOIETIC 
STEM CELL TRANSPLANTATION
Acute Graft-Versus-Host Disease
aGVHD is one of the best studied post-HSCT complications because it remains a major 
barrier to the overall success of this procedure. Because the presentation is diverse and the 
diagnosis relies entirely on clinical symptoms, there has been a quest to develop and validate 
biomarkers to aid in early diagnosis and prognosis. Furthermore, many of these biomarkers 
are being developed as potential novel therapeutic targets. Table 2 features an overview of 
the most recent and validated biomarkers for aGVHD.
Genomic markers for the development and severity of aGVHD following HSCT have been 
investigated. In addition to the well-known risk of major histocompatibility complex 
disparity,3 single nucleotide polymorphisms (SNPs) for mismatches in minor 
histocompatibility antigens have also been found to be risk factors for the occurrence of 
aGVHD, and increasing genome-wide recipient mismatching results in a substantial 
increased risk for grades III–IV GVHD.4 Genomic markers remain complicated to 
investigate because of the need to understand the genome of the donor and the recipient pre-
HSCT and after HSCT, and the small effect of each SNP requires large cohorts of thousands 
of HSCT patients to get meaningful and reproducible data.5
Recent transcriptomics analysis in the nonhuman primate have found that blocking OX40L 
using the blocking antibody KY1005 helped to control Th1 cells while preserving the 
reconstitution of regulatory T cells (Tregs) and prolonged GVHD-free survival. There was 
an additional benefit when combined with sirolimus.6 This antibody is currently being tested 
in a clinical trial through the Pediatric Blood and Marrow Transplant Consortium.
A variety of proteomic markers have been studied, and the most validated and recent ones 
are presented in Table 2. Several of the interleukins and their receptors (IL-2, IL-2Rα, IL-6, 
IL-8, IL-12, and IL-18) have been investigated, and IL-2Rα and IL-6 have emerged as the 
most useful markers for aGVHD.7–9 Using a screen of patient plasma samples by 
competitive hybridization to arrays of antibodies specific for diverse proteins, the first 
biomarker panel for aGVHD, including 4 different proteins IL-2Ra, tumor necrosis factor 
receptor 1 (TNFR1), IL-8, and hepatocyte growth factor (HGF), was identified and validated 
in a training and validation set of hundreds of patients.9 Although Denileukin Diftitox, an 
anti-IL-2Rα antibody, did not show benefit for the treatment of aGVHD,10 IL-6 has been 
more promising for prophylaxis against aGVHD. The use of tocilizumab in a phase 1/2 trial 
demonstrated a decrease in occurrence of aGVHD but no overall survival advantage.7 
Stimulation 2 (ST2), the IL-33 receptor, is a marker that has been discovered through an 
unbiased tandem mass spectrometry approach and has been validated in several cohorts as a 
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diagnostic, prognostic, predictive, and response to treatment biomarker.8,11–17 It has been 
tested in a variety of patients with different conditioning, transplant donor source, and 
degrees of match.11,12 As early as day 7 or 14 after HSCT, it can serve as a prognostic 
marker for aGVHD and nonrelapsed mortality.8,14,18 Furthermore, it may be a promising 
therapeutic target. ST2 blockade in murine models has demonstrated the ability to decrease 
the severity of GVHD and associated mortality.19
Cellular markers have also been studied, including Tregs, CD146T cells, CD30, and 
invariant natural killer T cells.20–23 CD146-expressing T cells and upregulation of CCR5 (a 
chemokine receptor) were found to be prognostic for gastrointestinal (GI) GVHD as early as 
day 14 after HSCT.22 A phase 1 clinical trial for brentuximab vedotin, an antibody-drug 
targeting CD30, has been tested for steroid-refractory aGVHD. In this trial, there was almost 
a 40% response rate with 15% achieving complete remission.24
Organ-specific markers have also been discovered. Elafin, which is overexpressed in 
inflammatory skin disorders, was found to be associated with the diagnosis of skin GVHD.
25
 GI and liver GVHD markers include HGF, cytokeratine-18 fragments (KRT18), T-cell 
immunoglobulin domain and mucin domain (TIM-3), and regenerating isletderived 3-α 
(REG3α), with REG3 α emerging as the most validated biomarker specifically for GI 
GVHD with prognostic ability.26–28 Recently, hypothesis-driven markers such as 
amphiregulin have emerged. Amphiregulin, an epidermal growth factor receptor ligand, was 
found to accurately define patients with a high-risk Minnesota aGVHD risk score, and to 
predict steroid responsiveness and nonrelapsed mortality (NRM).29
Sinusoidal Obstruction Syndrome
SOS, previously known as veno-occlusive disease, is a serious post-HSCT complication that 
affects the sinusoidal endothelial cells of the liver. It has been reported to occur in up to 13% 
of HSCT recipients, and when severe, is associated with multiorgan failure and significant 
mortality.30 The diagnosis of SOS remains challenging because it is dependent mostly on 
clinical presentation and supported with blood work showing elevated bilirubin and 
ultrasound results of the liver demonstrating reversal of the hepatic flow.
Although many markers of coagulation, such as antithrombin, thrombomodulin, protein C, 
von Willebrand factor, and plasminogen activator inhibitor-1, have been found to be 
associated with SOS in early studies,31–33 these markers are nonspecific and have not been 
well validated in current HSCT populations. Given the endothelial involvement, markers of 
endothelial dysfunction have been investigated. Using state-of-the art proteomics, a panel of 
5 proteins (angiopoietin 2 [Ang2], hyaluronic acid [HA], vascular adhesion molecule-1 
[VCAM-1], ST2, and L-ficolin) has been identified and validated with diagnostic value. All 
biomarkers were found to be elevated with the exception of L-ficolin, which was reduced.34 
HA and VCAM-1, combined with L-ficolin on day 0 of HSCT, is an early prognostic panel 
of markers for SOS34 (Table 3).
Pulmonary Complications
Pulmonary complications remain a significant source of early transplant-related mortality. 
Part of the difficulty in treating post-HSCT pulmonary disease is the diverse infectious and 
Rowan and Paczesny Page 4
Clin Lab Med. Author manuscript; available in PMC 2020 April 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
noninfectious causes that are difficult to understand, diagnose, and treat. Complications, 
such as IPS, require ruling out infectious causes before the institution of more specific IPS 
therapy. To that end, diagnostic markers for IPS have recently been identified. IL-6 and ST2 
are good diagnostic markers for IPS, and TNFR1 is able to distinguish IPS from underlying 
viral causes.35 This same group of biomarkers has been investigated for general respiratory 
failure, which carries up to a 60% mortality in this population.36 ST2 and IL-6 on day 7 after 
HSCT were found to be great prognostic markers for the future development of respiratory 
failure in an adult and pediatric cohort.37 However, these findings need to be validated in an 
independent cohort. Biomarkers for pulmonary complication offer the benefit of not only 
early prognosis but also a method to understand potential underlying biology of the disease 
process and offer new therapeutic targets.
Other Early Transplant Complications
Biomarkers for other early post-HSCT complications have also been investigated. 
Posttransplant diabetes mellitus (PTDM) has been reported in both pediatric and adult 
patients who have undergone allogeneic HSCT.38 There is an association with 
hyperglycemia in adults after HSCT and the occurrence of GVHD and overall mortality.39,40 
As such, early identification and institution of therapy are important for this population. A 
large adult cohort revealed that elevated ST2 was associated with PTDM.41 This association 
held when investigated in an isolated pediatric cohort.42
Thrombotic microangiopathy (TMA) is a post-HSCT complication associated with 
endothelial injury and complement activation that can lead to increased mortality and 
morbidity.43 Many organs can be affected leading to multiorgan dysfunction and death. 
Diagnosis of this disease is challenging because of lack of uniformed acceptance of 
diagnostic criteria.44 Discovery of specific biomarkers may lead to improved therapeutic 
decisions. Recently, ST2 on day 14 after HSCT has been found elevated in patients with 
TMA.45
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KEY POINTS
• Biomarkers should be categorized into diagnostic, prognostic, predictive, and 
response to treatment biomarkers based on the 2014 National Institutes of 
Health consensus report.
• Several proteomic biomarkers for acute graft-versus-host disease have been 
investigated by unbiased or hypothesis-driven approaches. Stimulation 2 has 
been the most validated and is a promising therapeutic target.
• Discovery of additional biomarkers for other posttransplant complications is 
ongoing and may improve diagnosis, prognosis, and the development of new 
therapeutic strategies.
Rowan and Paczesny Page 9
Clin Lab Med. Author manuscript; available in PMC 2020 April 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
There are several steps involved in the development of a biomarker for clinical use. The first 
step is a discovery phase that usually compares 20 to 40 cases and controls. This is often 
done with mass spectrometry. Candidate biomarkers are biomarkers that are often chosen 
based on biologic plausibility. Studies of candidate biomarkers are hypothesis driven. These 
markers often are in the early phases of study and lack extensive validation. Once a newly 
discovered biomarker demonstrates promising statistical association, validation must be 
performed. This is usually done using high-throughput immunoassay. The cohorts should be 
independent, and the validation is stronger if the cohort is large and from multiple 
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institutions. Finally, the biomarker should be verified. This is often done in large prospective 
studies that can help to determine cutoffs for high or low risk for a specific outcome.
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Table 1
Categories of biomarkers as defined by the National Institutes of Health working group
Category Definition Example
Diagnostic • Can help a clinician identify a disease rapidly so that 
treatment can be initiated
• Can help to differentiate diseases with similar clinical 
presentations
REG3α can help to differentiate Gl GVHD 
from other causes of non-GVHD diarrhea28
Prognostic • Can aid the clinician in the anticipated course of disease
• Can also help determine the likelihood of developing a 
particular complication
A panel of HA, VCAM, and L-ficolin drawn 
on day 0 of HSCTcan serve as a prognostic 
panel for the future development of SOS34
Predictive • Measured before therapy is initiated
• Helps to determine how a disease will progress following 
therapy
• Can give information on how a patient will respond to a 
particular treatment of intervention
ST2 can serve as a predictive marker for 
response to therapy for GVHD14
Response to 
treatment
• Measured after therapy is initiated
• Can help monitor therapeutic response
• Could potentially be used as a substitute for a clinical 
response
MAGIC biomarkers (ST2 and Reg3α) 
measured at 1 wk after initiation of steroids 
can predict steroids resistant disease and 
nonrelapsed mortality16
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Table 3
Biomarkers for sinusoidal obstructive syndrome after HSCT
Name Study (n)
Biomarker 
Type Associations and Time Points in SOS
Ang2, HA, L-
ficolin, ST2, 
VCAM
Akil et al,34 
2015
40 discovery Diagnostic • Composite panel for the diagnosis of SOS
• All markers increased except L-ficolin, which is 
decreased
45 training set
35 validation
HA, L-ficolin, 
VCAM
Akil et al,34 
2015
Derived from 
cohort above
Prognostic • Prognostic panel at day 0 of HSCT for the 
development of SOS
• All markers increased except L-ficolin, which is 
decreased
L-ficolin Abu Zaid etal,15 
2017
211 Prognostic • Low level on day 28 was associated with the 
development of SOS
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